| 证券代码 | RLM.O |
| 证券名称 | Realm Therapeutics plc ADR |
| 证券类型 | 美国存托凭证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2018-07-05 |
| 首发价格(元) | 12.76 USD |
| 首发数量(股) | 5074316 |
| 首发募资额(元) | 64,748,272.16 USD |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Realm Therapeutics plc |
| 注册地址 | - |
| 办公地址 | 267 Great Valley Parkway, Malvern, Pennsylvania, USA |
| 成立日期 | 2006-04 |
| 董事会主席 | - |
| 公司属地 | United Kingdom 英国 |
| 公司网址 | www.realmtx.com |
| 电话 | +1 (484) 321-2700 |
| 传真 | +1 (484) 321-2725 |
| 公司简介 | Realm Therapeutics plc is a biopharmaceutical company which focuses on leveraging its proprietary immunomodulatory technology to protect and improve the health of adults and children. Its lead product is PR022. It operates in two segments that are Drug Development and Wound Care, and Company and Corporate. The Drug Development and Wound Care segment generates maximum revenue for the company. |